Document Detail


Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
MedLine Citation:
PMID:  11157029     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To investigate the toxicity profile, activity, and pharmacokinetics of a novel L-nucleoside analog, troxacitabine (BCH-4556), in patients with advanced leukemia. PATIENTS AND METHODS: Patients with refractory or relapsed acute myeloid (AML) or lymphocytic (ALL) leukemia, myelodysplastic syndromes (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP). Troxacitabine was given as an intravenous infusion over 30 minutes daily for 5 days. The starting dose was 0.72 mg/m(2)/d (3.6 mg/m(2)/course). Courses were given every 3 to 4 weeks according to toxicity and antileukemic efficacy. The dose was escalated by 50% until grade 2 toxicity was observed, and then by 30% to 35% until the dose-limiting toxicity (DLT) was defined. RESULTS: Forty-two patients (AML: 31 patients; MDS: six patients [five MDS + one CMML]; ALL: four patients; CML-BP: one patient) were treated. Median age was 61 years (range, 23 to 79 years), and 29 patients were males. Stomatitis and hand-foot syndrome were the DLTs. The MTD was defined as 8 mg/m(2)/d. The pharmacokinetic behavior of troxacitabine is linear over the dose range of 0.72 to 10.0 m/m(2). Approximately 69% of troxacitabine was excreted as unchanged drug in the urine. Marrow hypoplasia occurred between days 14 and 28 in 73% of AML patients. Three complete remissions and one partial remission were observed in 30 assessable AML patients. One MDS patient achieved a hematologic improvement. A patient with CML-BP achieved a return to chronic phase disease. CONCLUSION: Troxacitabine has a unique metabolic and pharmacokinetic profile and significant antileukemic activity. DLTs were stomatitis and hand-foot syndrome. Troxacitabine merits further study in hematologic malignancies.
Authors:
F J Giles; J E Cortes; S D Baker; D A Thomas; S O'Brien; T L Smith; M Beran; C Bivins; J Jolivet; H M Kantarjian
Related Documents :
15136219 - Levels of minimal residual disease detected by quantitative molecular monitoring herald...
17652839 - Immunophenotypic subtyping of leukemic cells from iranian patients with acute lymphobla...
20072149 - Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressi...
12525519 - Additional prognostic value of bone marrow histology in patients subclassified accordin...
14962259 - Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and ...
15048069 - Voriconazole for the treatment of disseminated nodular cutaneous aspergillosis in a pat...
12397459 - Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectiona...
20581139 - Segmental innervation in lumbosacral transitional vertebrae (lstv): a comparative clini...
17502469 - Atherosclerotic burden and early mortality in acute ischemic stroke.
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase I; Journal Article    
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  19     ISSN:  0732-183X     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2001 Feb 
Date Detail:
Created Date:  2001-02-22     Completed Date:  2001-03-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  762-71     Citation Subset:  IM    
Affiliation:
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston 77030-4095, USA. frankgiles@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adult
Aged
Antineoplastic Agents / adverse effects*,  pharmacokinetics,  therapeutic use
Blast Crisis / drug therapy,  metabolism
Cytosine / adverse effects*,  analogs & derivatives*,  pharmacokinetics,  therapeutic use
Dioxolanes / adverse effects*,  pharmacokinetics,  therapeutic use
Dose-Response Relationship, Drug
Female
Humans
Leukemia / drug therapy*,  metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy,  metabolism,  pathology
Leukemia, Myeloid / drug therapy,  metabolism
Male
Middle Aged
Myelodysplastic Syndromes / drug therapy,  metabolism
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy,  metabolism
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Dioxolanes; 145918-75-8/troxacitabine; 71-30-7/Cytosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neutropenic enterocolitis in patients with acute leukemia: prognostic significance of bowel wall thi...
Next Document:  Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative dis...